PROTEIN KINASE CK1 ALPHA INACTIVATION CAUSES MANTLE CELL LYMPHOMA GROWTH ARREST AND SYNERGISTICALLY ENHANCES IBRUTINIB CYTOTOXICITY

EHA Library, Sabrina Manni, 266327

INTEGRATING DETECTION OF COPY NEUTRAL CHROMOSOMAL LOSSES IN A CLINICAL SETTING IN LEUKEMIA AND LYMPHOMA BY MEANS OF ALLELIC IMBALANCE AND READ DEPTH RATIO COMPARISON

EHA Library, Marcus C. Hansen, 266328

PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

EHA Library, Lara Crucitti, 266329

CORRELATION OF CD10 EXPRESSION DETERMINED BY FLOW CYTOMETRIC IMMUNOPHENOTYPING AND CELL-OF-ORIGIN DETERMINATION BY GENE EXPRESSION PROFILING IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Ryan S. Robetorye, 266330

TRANSFORMING ACTIVITIES OF THE NUP98-KMT2A FUSION GENE ASSOCIATED WITH MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA

EHA Library, J Neil Fisher, 266331

INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES.

EHA Library, Suguru Morimoto, 266332

MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

EHA Library, Marta Martín Izquierdo, 266333

COPY NUMBER VARIATIONS AND UNIPARENTAL DISOMY PREDICT POOR SURVIVAL IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE AND ARE ASSOCIATED WITH MACROCYTOSIS

EHA Library, Stine Ulrik Mikkelsen, 266334

CLINICAL AND MOLECULAR CHARACTERISTICS OF SRSF2-MUTATED NEOPLASMS.

EHA Library, GABRIELE TODISCO, 266335

THE EFFECT OF 5-AZACITIDINE TREATMENT ON THE OF BONE MARROW MESENCHYMAL STEM TRANSCRIPTOME IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Ioannis Liapis, 266336

THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME

EHA Library, Zoi Bezirgiannidou, 266337

GENETIC EVOLUTION PATTERNS IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA TO SECONDARY ACUTE MYELOID LEUKEMIA: AN ANALYSIS OF 36 PAIRED SAMPLES

EHA Library, Yi Jiun Su, 266338

MIR-223 IS SUPPRESSED IN EXOSOMES OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND MAY BE A MARKER OF RESIDUAL GRANULOCYTIC-MONOCYTIC DIFFERENTIATION

EHA Library, Bruno D Benites, 266339

TERT PROMOTER METHYLATION AS A POTENTIAL PROGNOSTIC BIOMARKER FOR PROGRESSION OF UNEXPLAINED CYTOPENIA TO MDS AND AML

EHA Library, Katja Kaastrup, 266340

TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Teresa Ezponda, 266341

MITOCHONDRIAL GENOMIC ANALYSIS IN PATIENTS WITH MYELOID MALIGNANCIES

EHA Library, Seon Young Kim, 266342

PROMOTER METHYLATION OF TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA

EHA Library, Naoki Mori, 266343

THE DIFFERENT MUTATIONAL LANDSCAPES OF A PANEL GENES BY NEXT GENERATION SEQUENCING IN 967 CASES OF MDS AND AML

EHA Library, Yanfang Liu, 266344

EASIX FOR PREDICTION OF SURVIVAL IN LOWER RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Almuth Merz, 266345

THE SFGM-TC MDS SCORE AT DAY 180 IS ASSOCIATED WITH POST-TRANSPLANT OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WHO UNDERWENT CD34+ SELECTED ALLOGENEIC STEM CELL TRANSPLANT

EHA Library, Ana Alarcon, 266346

FACTORS ASSOCIATED WITH THE NEED FOR TRANSFUSIONS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME (MDS). DATA FROM THE REGULAR CARE MDS-REGISTRY IN GERMANY

EHA Library, H Tilman Steinmetz, 266347

PROGNOSTIC MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME TREATED WITH HEMATOPOIETIC STEM-CELL TRANSPLANTATION

EHA Library, Zixian Liu, 266348

AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATE TO R-IPSS SCORE BUT NOT TO OVERALL SURVIVAL OR LEUKEMIC EVOLUTION IN MYELODYSPLASTIC SYNDROMES

EHA Library, Thomas Brunet, 266349

AZACITIDINE (VIDAZA®) IN PEDIATRIC PATIENTS WITH RELAPSED ADVANCED MDS: RESULTS OF A PHASE I/II STUDY BY THE ITCC CONSORTIUM AND THE EWOG-MDS GROUP: STUDY ITCC-015

EHA Library, Natasha van Eijkelenburg, 266350

CD10 EXPRESSION ON MYELOID PRECURSOR CELLS (CD34 + CD117 +) AS A PREDICTIVE FACTOR FOR PROGRESSION OF PRIMARY MYELODISPLASTIC SYNDROMES

EHA Library, Natalia Milanovich, 266351

PATIENT-REPORTED OUTCOME MEASURES IN CLINICAL STUDIES FOR MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA: A LITERATURE REVIEW AND LANDSCAPE ANALYSIS

EHA Library, Reinhard Stauder, 266352

CLONES WITH COMPLEX ABERRATIONS AND TP53 MUTATIONS RESPOND TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

EHA Library, Christina Ganster, 266353

A GENOME-WIDE CRISPR SCREEN IDENTIFIES TOP2B AS AN ACQUIRED DRUGGABLE VULNERABILITY IN THE CONTEXT OF IMID RESISTANCE

EHA Library, Matteo Costacurta, 266354

PROGNOSTIC VALUE OF NEXT GENERATION FLOW MONITORING CIRCULATING TUMOR PLASMA CELLS IN PERIPHERAL BLOOD ON MYELOMA PATIENTS AFTER TREATMENT

EHA Library, Luzalba Sanoja-Flores, 266355

PRECLINICAL EVALUATION OF THE NEW GPRC5DXCD3 (JNJ-7564) BISPECIFIC ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Christie Verkleij, 266356

THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY

EHA Library, Rocio Montes de Oca, 266357

IBERDOMIDE (CC-220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE-DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT

EHA Library, Michael Amatangelo, 266358

A MATURATION INDEX DEFINES NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH ADVANCED IMMUNOPHENOTYPIC AND MOLECULAR DIFFERENTIATION PROFILES ASSOCIATED WITH POOR PROGNOSIS

EHA Library, Marina Martello, 266359

DUAL-TARGETING OF PROMOTER AND ENHANCER DRIVEN PROCESSES SUPPRESSES MYELOMA CELL GROWTH AND VIABILITY VIA PERTURBATION OF THE MYELOMA PROLIFERATIVE PROGRAM.

EHA Library, Mariateresa Fulciniti, 266360

BLOCKING OF WIP1 PHOSPHATASE OVERCOMES BORTEZOMIB RESISTANCE AND PROMOTES CELL DEATH VIA ER STRESS-INDUCED APOPTOTIC JNK/C-JUN SIGNALING: NOVEL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

EHA Library, Katia Beider, 266361

MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Nouf Alrasheed, 266362

OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY

EHA Library, Shaji Kumar, 266363

MM-BMSCS INDUCE IMMUNOSENESCENT NAÏVE CD4+ T-CELLS THROUGH THE NOVEL INTERCELLULAR COMMUNICATION - TUNNELING NANOTUBES

EHA Library, Yadan Wang, 266364

INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY

EHA Library, Alejandra Ortiz, 266365

CHROMATIN ACTIVATION AS A UNIFYING PRINCIPLE UNDERLYING PATHOGENIC MECHANISMS IN MULTIPLE MYELOMA

EHA Library, Raquel Ordoñez, 266366

INVESTIGATING MECHANISMS OF ELOTUZUMAB AND LENALIDOMIDE THERAPY IN MULTIPLE MYELOMA

EHA Library, Kelden J Richardson, 266367

CARFILZOMIB TREATMENT CAUSES RETICULOCYTOSIS BY IMPAIRING TERMINAL ERYTHROID MATURATION IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Nicolas Kint, 266369

IDENTIFICATION OF HLA-E AS A KEY GENE IN MULTIPLE MYELOMA BASED ON BIOINFORMATIC ANALYSIS AND DESIGN HIGH-AFFINITY PEPTIDES TARGETING HLA-E BASED ON COMPUTATIONAL TECHNIQUES

EHA Library, Ying Yang, 266370

ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE- AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA

EHA Library, Takuto Tachita, 266371

SINGLE CELL RNA-SEQ REVEALED A RARE ITGA2 EXPRESSING CELL SUBPOPULATION WITH DISTINCT CANCER STEM CELL MARKER SIGNATURE IN MULTIPLE MYELOMA

EHA Library, Margaret HL Ng, 266372

TARGETED ULTRA-DEEP NGS ASSESSMENT OF TP53 MUTATIONS IN MULTIPLE MYELOMA FROM WHOLE BONE MARROW

EHA Library, Anna PETRACKOVA, 266373

OVEREXPRESSION DNP73 PROMOTES THE PROLIFERATION AND DRUG RESISTANCE OF MULTIPLE MYELOMA

EHA Library, Jie Xu, 266374

NONSENSE-MEDIATED MRNA DECAY IS A THERAPEUTIC TARGET IN MULTIPLE MYELOMA

EHA Library, Alexander Leeksma, 266375

TARGETING PROTEIN ARGININE METHYLTRANFERASE PRMT5 IN HIGH-RISK MULTIPLE MYELOMA: A NEW TREATMENT STRATEGY?

EHA Library, Ken Maes, 266376

THE BONE MARROW MICROENVIRONMENT OF MULTIPLE MYELOMA PROMOTES MYELOMA RELATED ANEMIA BY SUPPRESSING THE DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS

EHA Library, Lanting Liu, 266377

TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS` CHARACTERISTICS IN MULTIPLE MYELOMA.

EHA Library, Paola Omedé, 266378

PIWIL1 PROMOTES DRUG RESISTANCE IN MULTIPLE MYELOMA THROUGH MODULATING MITOPHAGY

EHA Library, Wu Qiuling, 266379

FUNCTIONAL HIGH-THROUGHPUT SCREENING FOR IDENTIFICATION OF NOTCH1 DOWNSTREAM EFFECTORS AS NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA

EHA Library, Daniela Maichl, 266380

PARTICIPATION OF IMMUNE RESPONSE GENES POLYMORPHISM IN THE OCCURRENCE OF SOLID TUMORS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Elena Nazarova, 266381

COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA

EHA Library, Arantxa Carrasco, 266382

C-MYC-DRIVEN AND PRMT5-DEPENDENT REGULATION OF MULTIPLE MYELOMA CELL PROLIFERATION THROUGH SMCHD1 GENE

EHA Library, Peipei Xu, 266383

GENE-EXPRESSION PROFILE OF HIGH-DENSITY NEUTROPHILS REVEALS PROGRESSIVE DIFFERENCES IN MGUS AND MULTIPLE MYELOMA, ASSOCIATED WITH REDUCED PHAGOCYTOSIS AND INCREASED INFECTION SUSCEPTIBILITY

EHA Library, ALESSANDRA ROMANO, 266384

SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY

EHA Library, Alessandra Larocca, 266385

SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Christine Chen, 266386

SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

EHA Library, Rao Prabhala, 266387

MULTIPLE HIGH-RISK CYTOGENETIC ABERRATIONS CONFER A PROGRESSIVELY NEGATIVE IMPACT ON SURVIVALS OF NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Xue-Han Mao, 266388

MONITORING THE CYTOGENETIC ARCHITECTURE OF MINIMAL RESIDUAL PLASMA CELLS INDICATES THE THERAPY-INDUCED CLONAL SELECTION IN MULTIPLE MYELOMA.

EHA Library, Yuting Yan, 266389

EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

EHA Library, Meletios A. Dimopoulos, 266390

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

EHA Library, Cyrille Hulin, 266391

THE IMPACT OF RESPONSE KINETICS FOLLOWING INITIAL THERAPY FOR MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS

EHA Library, Yuting Yan, 266392

BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Laura Rosiñol, 266393

Pomalidomide + Bortezomib + Low-Dose Dexamethasone vs Bortezomib + Low-Dose Dexamethasone After One Prior Line of Therapy in Patients With Lenalidomide-Pretreated Multiple Myeloma: Subgroup Analysis of the Phase 3 OPTIMISMM Trial

EHA Library, Meletios Dimopoulos, 266394

EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

EHA Library, Katja Weisel, 266395

HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL

EHA Library, Elias K. Mai, 266396

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

EHA Library, Cyrille Hulin, 266397

EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL

EHA Library, Elizabeth PHILLIPS, 266398

IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

EHA Library, Xue-Han Mao, 266399

EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY

EHA Library, Ajai Chari, 266400

OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

EHA Library, Vittorio MONTEFUSCO, 266401

FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA

EHA Library, Aurore Perrot, 266402

THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA (ALLG) GROUP MM17 TRIAL: RESPONSE ADAPTIVE SALVAGE WITH CARFILZOMIB-THALIDOMIDE-DEXAMETHASONE FOR MULTIPLE MYELOMA PATIENTS FAILING FRONT-LINE BORTEZOMIB

EHA Library, Andrew Spencer, 266403

SYSTEMATIC LITERATURE REVIEW AND NETWORK-META ANALYSIS COMPARING INDUCTION TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE TRANSPLANT ELIGIBLE SETTING

EHA Library, John Ashcroft, 266404

ADVERSE IMPACT OF PRIOR THERAPY ON TRANSPLANT OUTCOME IN MULTIPLE MYELOMA

EHA Library, Amani Erra, 266405

MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012-03).

EHA Library, Arthur Bobin, 266406

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR

EHA Library, Ludek Pour, 266407

HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT

EHA Library, Noemi Puig, 266408

OUTCOMES FOR TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVING LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE, OR BORTEZOMIB AND DEXAMETHASONE: AN ENHANCED DATABASE ANALYSIS

EHA Library, Ajai Chari, 266409

MULTIPLE DRUG COMBINATIONS FOR FIRST-LINE TREATMENT IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

EHA Library, Vanessa Piechotta, 266410

ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 266411

CLINICAL UTILITY OF [18F]FLORBETABEN PET/CT SCAN FOR IMAGING AMYLOIDOSIS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Jae-Cheol Jo, 266412

PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

EHA Library, Alessandra Tedeschi, 266413

IMPACT OF PATIENTS CHARACTERISTICS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE CHARISMMA STUDY

EHA Library, Laura Rosiñol, 266414

REAL-WORLD USE OF THE TRIPLET REGIMEN CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A SUB-GROUP INTERIM ANALYSIS FROM A PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Xavier Leleu, 266415

IMPACT OF EARLY VS LATE RELAPSE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A SUB ANALYSIS OF THE PHASE 3 FIRST TRIAL

EHA Library, Thierry Facon, 266416

PROGNOSTIC IMPACT OF 18F-FDG PET/CT IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH RENAL IMPAIRMENT

EHA Library, Je-Jung Lee, 266417

LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE AS FIRST-LINE THERAPY IN TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: INTERIM RESULTS OF THE OBSERVATIONAL STUDY FIRST-NIS

EHA Library, Hans-Jürgen Hurtz, 266418

COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL

EHA Library, PARAMESWARAN HARI, 266419

REAL WORLD EXPERIENCE IN THE MANAGEMENT OF WALDENSTRÖM’S MACROGLOBULINAEMIA FROM ANALYSIS OF THE RORY MORRISON REGISTRY

EHA Library, Joshua BOMSZTYK, 266420

CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 266421

PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

EHA Library, SHINSUKE IIDA, 266422

VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS

EHA Library, M Hasib Sidiqi, 266424

HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3

EHA Library, Fredrik Schjesvold, 266425

SERUM CEREBLON LEVELS PREDICT FIVE- YEAR POST LEALIDOMIDE/DEXAMETHASONE (RD) SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS AND CORRELATE WITH DISEASE CHARACTERISTICS.

EHA Library, Annita-Ioanna Gkioka, 266426

O-12-M1: AN EVALUATION OF TIME TO NEXT TREATMENT IN MELFLUFEN AND DEXAMETHASONE-TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sara Bringhen, 266427

CONSOLIDATION FOLLOWING INFUSIONAL DPACE IMPROVES OUTCOMES IN NOVEL AGENT RELAPSED/REFRACTORY MYELOMA PATIENTS

EHA Library, Faouzi Djebbari, 266428